Artículos por temáticas

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Brunden KR.

J Neurosci. 2012 Mar 14;32(11):3601-11. doi: 10.1523/JNEUROSCI.4922-11.2012.

[Melatonin agonist: a possible disease-modifying agent for Alzheimer's disease]

Matsubara E.

Nihon Rinsho. 2012 Feb;70(2):349-52.

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics

Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA.

J Alzheimers Dis. 2012;32(4):905-18. doi: 10.3233/JAD-2012-121075.

[Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease]

Andrieux K, Couvreur P.

Biol Aujourdhui. 2012;206(3):185-90. doi: 10.1051/jbio/2012019. Epub 2012 Nov 22.

Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial

Saxton J, Hofbauer RK, Woodward M, Gilchrist NL, Potocnik F, Hsu HA, Miller ML, Pejović V, Graham SM, Perhach JL.

J Alzheimers Dis. 2012;28(1):109-18. doi: 10.3233/JAD-2011-110947.

A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies

Sun N, Funke SA, Willbold D.

Mini Rev Med Chem. 2012 May;12(5):388-98. doi: 10.2174/138955712800493942.

[Effects of a psychological group intervention on neuropsychiatric symptoms and communication in Alzheimer's dementia]

Fischer-Terworth C, Probst P.

Z Gerontol Geriatr. 2012 Jul;45(5):392-7. doi: 10.1007/s00391-012-0296-4.

Cardiac safety of donepezil in elderly patients with Alzheimer disease

Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E.

Intern Med. 2012;51(6):575-8. doi: 10.2169/internalmedicine.51.6671. Epub 2012 Mar 15.

Relapse risk after discontinuation of risperidone in Alzheimer's disease

Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B.

N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058.

Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia

Nasab NM, Bahrammi MA, Nikpour MR, Rahim F, Naghibis SN.

J Pak Med Assoc. 2012 Jul;62(7):677-80.

[Intended pharmacotherapeutical approaches of Alzheimer's disease therapy]

Korábecný J, Hrubá E, Soukup O, Zemek F, Musílek K, Nepovímová E, Spilovská K, Opletalová V, Kuca K.

Ceska Slov Farm. 2012 Feb;61(1-2):4-10.

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease

Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J.

Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):421-32. doi: 10.1177/1533317512454708.

Development of an observer rating scale for caregiver communication in persons with Alzheimer's disease

Williams CL, Parker C.

Issues Ment Health Nurs. 2012 Apr;33(4):244-50. doi: 10.3109/01612840.2011.653040.

Natural products as a rich source of tau-targeting drugs for Alzheimer's disease

Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ.

Future Med Chem. 2012 Sep;4(13):1751-61. doi: 10.4155/fmc.12.124.

Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease

Zhang C.

Discov Med. 2012 Sep;14(76):189-97.